Dosing begins in trial of potential therapy for GBA1 Parkinson’s
Dosing has begun in a Phase 1 clinical trial that is testing GT-02287, an experimental oral medication being developed to treat Parkinson’s disease caused by mutations in the GBA1 gene. The first two participants in the trial have been dosed, according to the therapy’s developer, Gain Therapeutics. “Initiating first-in-human…